^
Association details:
| Biomarker: | BRCA1 2080delA + CCNE1 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | fadraciclib (CYC065) (CDK9 inhibitor, CDK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
Published date:
08/31/2021
Excerpt:
The BRCA1 2080delA model has high expression of cyclin E1, probably driven in part by CCNE1 copy number gain (1.31× from exome sequencing). In this model we found that both single agent olaparib and fadraciclib were effective, leading to a significant reduction in tumor volume.
DOI:
https://doi.org/10.1038/s41523-021-00312-x
